home / stock / btggf / btggf short
Short Information | Btg Plc (OTCMKTS:BTGGF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 905 |
Total Actual Volume | 1,578 |
Short Trends | |
---|---|
Cover Days | 5 |
Short Days | 13 |
No Change Days | 2 |
Averages | |
---|---|
Average Short Volume | 45 |
Average Short Percentage | 68.58% |
Is there a BTGGF Short Squeeze or Breakout about to happen?
See the BTGGF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-18-2024 | $0 | $58.4 | $0 | $0 | 1 | 1 | 100% |
04-16-2024 | $0 | $58.4 | $0 | $0 | 1 | 1 | 100% |
03-15-2024 | $58 | $59.76 | $59.76 | $58 | 378 | 100 | 26.46% |
03-14-2024 | $0 | $59.76 | $0 | $0 | 4 | 2 | 50% |
03-13-2024 | $59.4 | $59.76 | $59.76 | $57.86 | 335 | 300 | 89.55% |
03-11-2024 | $0 | $43.65 | $0 | $0 | 10 | 10 | 100% |
03-04-2024 | $0 | $43.65 | $0 | $0 | 28 | 1 | 3.57% |
02-29-2024 | $0 | $43.65 | $0 | $0 | 5 | 5 | 100% |
02-26-2024 | $43.65 | $43.65 | $43.65 | $43.65 | 100 | 100 | 100% |
01-19-2024 | $0 | $44.46 | $0 | $0 | 1 | 1 | 100% |
01-18-2024 | $0 | $44.46 | $0 | $0 | 99 | 49 | 49.49% |
01-16-2024 | $0 | $44.46 | $0 | $0 | 4 | 1 | 25% |
01-12-2024 | $44.46 | $44.46 | $44.46 | $44.46 | 242 | 200 | 82.64% |
01-11-2024 | $47.26 | $44.45 | $47.26 | $44.45 | 295 | 112 | 37.97% |
12-27-2023 | $0 | $35.95 | $0 | $0 | 46 | 4 | 8.7% |
12-05-2023 | $0 | $25 | $0 | $0 | 10 | 8 | 80% |
12-01-2023 | $0 | $25 | $0 | $0 | 11 | 2 | 18.18% |
11-30-2023 | $0 | $25 | $0 | $0 | 1 | 1 | 100% |
11-13-2023 | $0 | $25 | $0 | $0 | 4 | 4 | 100% |
11-03-2023 | $0 | $19.5 | $0 | $0 | 3 | 3 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Btg Plc Company Name:
BTGGF Stock Symbol:
OTCMKTS Market:
Supported by comparative Dosisphere data, a phase II multicentric randomised dosimetry trial LONDON , July 23, 2019 /PRNewswire/ -- BTG plc (LSE: BTG), a global healthcare company, today announced consensus recommendations for personalised treatment for hepatocellular carcinoma (HCC) ...